(NYSE MKT: CVM)
reports financial results for the fiscal quarter ended December 31, 2012.
CEL-SCI reported that net loss available to shareholders for the quarter ended December 31, 2012 was ($2,310,246) versus ($4,156,833) during the same quarter ended December 31, 2011. Net loss per common share, (basic) was ($0.01) for the quarter ended December 31, 2012 versus ($0.02) during the same quarter ended December 31, 2011. The operating loss for the quarter ended December 31, 2012 was ($5,044,457) versus an operating loss of ($4,443,276) during the same quarter ended December 31, 2011.
R&D expenses for the quarter ended December 31, 2012 totaled $2,924,722 versus R&D expenses of $2,456,185 for the quarter ended December 31, 2011. R&D expenses increased because of the increased level of activity associated with conducting the Company’s Phase III clinical study.
The Company ended the December quarter with approximately $10,736,000 in cash and cash equivalents. During the quarter, the Company completed a Registered Direct financing, generating net proceeds of $9,807,000.
Geert Kersten, Chief Executive Officer said, “We continue to make significant progress in our pivotal global Phase III clinical trial of Multikine (Leukocyte Interleukin, Injection). We believe that we are well positioned both financially and operationally to support ongoing clinical activities with the goal of making Multikine a very important new treatment for head and neck cancer.”
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.